Exactech develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. The Company's operating segments are represented by its major product lines: knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes miscellaneous sales categories, such as surgical instruments held for sale, bone cement, instrument rental fees, shipping charges, and other implant product lines.
The Company manufactures some components of its knee, extremity, and hip joint replacement systems at its facility in Gainesville, Florida. Its joint replacement products are used by orthopedic surgeons to repair or replace joints that have deteriorated as a result of injury or disease. Exactech's spinal implants are used as an adjunct to the fusion of vertebrae in the treatment of spinal disease and deformity.
Exactech was founded in 1985 and is headquartered in Gainesville, US
Report incorrect company information
Exactech Office Locations
Exactech has offices in Gainesville, Capinghem, Bella Vista, Chūō-ku and in 10 other locations
Gainesville, US (HQ)
2320 NW 66 Ct
Bella Vista, AU
2 14 Lexington Dr
Caledonia, CA
322 Argyle St S
Capinghem, FR
Rue de la Zamin
La Tronche, FR
5 Avenue du Grand Sablon
Ostwald, FR
Rue d'Illkirch
Report incorrect company information
Exactech Financials and Metrics
Summary Metrics
Founding Date | 1985 |
Exactech is a subsidiary of TPG
Exactech Financials
Exactech's revenue was reported to be $257.57 m in FY, 2016 which is a 6.5% increase from the previous period.
Annual
| USD | FY, 2013 | FY, 2014 | Y, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 237.1 m | 248.4 m | 241.8 m | 257.6 m |
Revenue growth, % | 5% | (3%) | 7% | |
Cost of goods sold | 73 m | 74.2 m | 73.6 m | 80.3 m |
Gross profit | 164.1 m | 174.1 m | 168.2 m | 177.3 m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 55.7 m | 63.3 m | 63.9 m | 57.9 m | 61.4 m | 61.5 m | 56.2 m | 65.3 m | 66.1 m | 59.9 m | 69.5 m | 67.3 m | 61.4 m |
Cost of goods sold | 16.1 m | 18.6 m | 19.6 m | 16.9 m | 18.6 m | 19.3 m | 16.6 m | 20.4 m | 20.3 m | 18.8 m | 20.6 m | 21.1 m | 18.2 m |
Gross profit | 39.5 m | 44.6 m | 44.4 m | 41 m | 42.7 m | 42.2 m | 39.6 m | 44.9 m | 45.9 m | 41.1 m | 48.8 m | 46.3 m | 43.2 m |
Gross profit Margin, % | 71% | 71% | 69% | 71% | 70% | 69% | 70% | 69% | 69% | 69% | 70% | 69% | 70% |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 6 m | 10.1 m | 12.7 m | 13.1 m |
Accounts Receivable | 59.1 m | 50.7 m | 52.4 m | 99.1 m |
Inventories | 71.6 m | 72.8 m | 71.4 m | 65.3 m |
Current Assets | 142.6 m | 139.2 m | 141.4 m | 143.1 m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 6.8 m | 11.3 m | 11 m | 9.1 m | 12.3 m | 14.9 m | 17.1 m | 9.1 m | 10.1 m | 12.6 m | 11.2 m | 8.9 m | 11.7 m |
Current Assets | 141.8 m | 136.9 m | 141 m | 135.9 m | 141.4 m | 145.7 m | 145.9 m | 140.9 m | 143.6 m | 144.7 m | 140.5 m | 142.2 m | 143 m |
Goodwill | 13.4 m | 13.5 m | 13.5 m | 13.2 m | 17.4 m | 19 m | 19.1 m | 22.6 m | 22.3 m | 22.5 m | 14.2 m | 14.8 m | 14.9 m |
Total Assets | 261.9 m | 255.8 m | 262.2 m | 257.9 m | 272.5 m | 274.5 m | 277.2 m | 290.7 m | 295.8 m | 300.1 m | 297.1 m | 301.8 m | 307.2 m |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 15.4 m | 16.5 m | 14.8 m | 162 k |
Depreciation and Amortization | 17.6 m | 18.5 m | 16.9 m | 18 m |
Inventories | (9.7 m) | (9.1 m) | (6.9 m) | (15.7 m) |
Accounts Payable | 910 k | (2.7 m) | (1.2 m) | 2.4 m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 3.2 m | 4.2 m | 4.2 m | 3 m | 4.1 m | 3.7 m | 2.9 m | 4.4 m | 4.4 m | 3.2 m | 4.6 m | 2.9 m |
Depreciation and Amortization | 4 m | 4.3 m | 4.1 m | 4.3 m | 4.4 m | 4.2 m | 4.1 m | 4.3 m | 4.4 m | 4.6 m | 4.7 m | |
Accounts Payable | 17.4 m | 15.6 m | 14.2 m | 13.3 m | 12.6 m | 17.1 m | 15.9 m | 14.1 m | 16.7 m | 18.3 m |
Report incorrect company information
Exactech News and Updates
April 23, 2018
Bone Cement 2018 Global Market Key Players – Smith & Nephew, Arthrex, DJO Global, Exactech – Analysis and Forecast to 2023
WiseGuyRerports.com Presents “Bone Cement-Global Market Status and Trend Report 2013-2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday
February 15, 2018
TPG Capital completes take-private Exactech acquisition
TPG Capital has closed its previously announced take-private buyout of Exactech for $49.25 per share or about $737 million. Starting February 15, 2018, Exactech will no longer trade on the NASDAQ. Based in Gainesville, Florida, Exactech is a developer of orthopaedic implant devices and surgical inst…
January 17, 2018
Global Hip Replacement Implant Market 2017: Key Players – B. Braun, Exactech, DJO Global, Johnson & Johnson
WiseGuyReports.com adds “Hip Replacement Implant Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” Posted via Industry Today. Follow us on Twitter @IndustryToday
December 21, 2017
The Value of Hip Replacement Implant Market Estimated to Soar Higher at 3.9% CAGR During 2016-2024
Transparency Market Research has announced the addition of the “Hip Replacement Implant Market: Global Industry Analysis and Opportunity Assessment, 2016-2024"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday
December 18, 2017
Global Hip Reconstruction Devices Market : North America to Account US$2.11 bn in 2017
The overall opportunity in the global market for hip reconstruction devices was worth US$5.68 bn in 2016. Going forward, the technological advancements in these devices are anticipated to continue propelling this market over the next few years, bringing in exceptional growth. Posted via Industry Tod…
December 14, 2017
Hip Replacement Market Value to Swing Up US$ 9.1 Bn by 2024
Growth of the global hip replacement market is mainly driven by a rising geriatric population, rising incidences of fracture or injury to the hip, wearing down of the joint over time, or osteoarthritis amongst the aging population. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information